AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17156341 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP-FEIA
Number of subjects: 45
Study 17156341 — intervention group
Group type: EXPERIMENTAL
Intervention: RAST
Number of subjects: 45
Study 15659242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine high-dose therapy
Number of subjects: 37
Study 12516679 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush (MTB)
Number of subjects: 0
Study 12516679 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B 3D Excel (PTB1)
Number of subjects: 0
Study 12516679 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare Elite (PTB2)
Number of subjects: 0
Study 12516679 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased toothbrush force from 90 g to 150 g
Number of subjects: 0
Study 9805520 — intervention group
Group type: EXPERIMENTAL
Intervention: Human interactive personal contact with a member of an ICBC‐trained head restraint adjustment team
Number of subjects: 1974
Study 9805520 — intervention group
Group type: COMPARATOR
Intervention: Passive video presentation of the consequences of correct and incorrect head restraint adjustment
Number of subjects: 1974
Study 9805520 — intervention group
Group type: COMPARATOR
Intervention: Interactive three‐dimensional kinetic model showing the consequences of correct and incorrect head restraint adjustment
Number of subjects: 1974
Study 9805520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1974
Study 8543519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline 18.75 mg
Number of subjects: 0
Study 8543519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline 37.5 mg
Number of subjects: 0
Study 8543519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline 75 mg
Number of subjects: 0
Study 8543519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline 112.5 mg
Number of subjects: 0
Study 8543519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2102705 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-carbomethoxythiazolidine 400 mg/d
Number of subjects: 24
Study 2102705 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-carbomethoxythiazolidine 600 mg/d
Number of subjects: 24
Study 2102705 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-carbomethoxythiazolidine 200 mg/d (three times a day)
Number of subjects: 24
Study 2102705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2102705 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-carbomethoxythiazolidine 200 mg/d
Number of subjects: 24
Study 7406481 — intervention group
Group type: EXPERIMENTAL
Intervention: Alafosfalin 50 mg
Number of subjects: 0
Study 7406481 — intervention group
Group type: EXPERIMENTAL
Intervention: Alafosfalin 2500 mg
Number of subjects: 0
Study 7406481 — intervention group
Group type: EXPERIMENTAL
Intervention: Alafosfalin 500 mg plus Cephalexin 250 mg
Number of subjects: 0
Study 30247174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) with daclatasvir for 24 weeks without ribavirin (RBV)
Number of subjects: 150
Study 30247174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) with ledipasvir for 24 weeks without ribavirin (RBV)
Number of subjects: 150
Study 30247174 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients (SOF/daclatasvir or SOF/ledipasvir)
Number of subjects: 150
Study 30247174 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 150
Study 25587090 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-guided quality improvement intervention
Number of subjects: 38725
Study 23900590 — intervention group
Group type: EXPERIMENTAL
Intervention: Accu‐Chek Aviva Expert meter with an integrated bolus advisor
Number of subjects: 218
Study 23900590 — intervention group
Group type: COMPARATOR
Intervention: Standard BG meter and manual bolus calculation (Control group)
Number of subjects: 218
Study 21788433 — intervention group
Group type: EXPERIMENTAL
Intervention: Unshorn sheep (treatment group)
Number of subjects: 14
Study 21788433 — intervention group
Group type: COMPARATOR
Intervention: Shorn sheep (control group)
Number of subjects: 14
Study 21788433 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-shearing (treatment group)
Number of subjects: 14
Study 19800566 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-frequency TENS (80 pps)
Number of subjects: 36
Study 19800566 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-modulated TENS (20 to 100 pps)
Number of subjects: 36
Study 19800566 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS (no current)
Number of subjects: 36
Study 17074563 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity laser treatment
Number of subjects: 1052
Study 17074563 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 1052
Study 14992903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab (2.0 mg/kg bolus plus 0.05 mg/kg/h infusion for 24 hours)
Number of subjects: 914
Study 14992903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 914
Study 11720319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1,000 mg/d for 2 weeks (n = 7)
Number of subjects: 16
Study 11720319 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 20 mg/kg/d for 2 weeks (n = 9)
Number of subjects: 16
Study 9385282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal calcitonin 200 IU per day, divided in 2 doses
Number of subjects: 46
Study 9385282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 8015793 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper joint space lavage
Number of subjects: 33
Study 8015793 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lavage)
Number of subjects: 33
Study 2689468 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about asthma
Number of subjects: 91
Study 2689468 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral adjustment
Number of subjects: 91
Study 2689468 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions
Number of subjects: 91
Study 2689468 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 91
Study 2689468 — intervention group
Group type: EXPERIMENTAL
Intervention: Health locus of control
Number of subjects: 91
Study 4895341 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salicylate
Number of subjects: 13
Study 4895341 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 13
Study 4895341 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 13
Study 31404548 — intervention group
Group type: EXPERIMENTAL
Intervention: High CO state
Number of subjects: 214
Study 31404548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CO state without ECMO
Number of subjects: 214
Study 31404548 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 214
Study 31404548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from high CO
Number of subjects: 214
Study 31404548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to low CO
Number of subjects: 214
Study 31404548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition risk to ECMO
Number of subjects: 214
Study 31404548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CO and ECMO
Number of subjects: 214
Study 31404548 — intervention group
Group type: EXPERIMENTAL
Intervention: High SVR state
Number of subjects: 214
Study 31163974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive volume removal with stepped pharmacological therapy
Number of subjects: 105
Study 31163974 — intervention group
Group type: COMPARATOR
Intervention: Fixed rate ultrafiltration
Number of subjects: 105
Study 31163974 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in renal tubular injury biomarkers
Number of subjects: 105
Study 28199818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg once per day)
Number of subjects: 157
Study 28199818 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg once per day; 4 weeks on, 2 weeks off)
Number of subjects: 157
Study 25956286 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidose-isotretinoin (Cip-Iso)
Number of subjects: 358
Study 25956286 — intervention group
Group type: COMPARATOR
Intervention: Accutane®
Number of subjects: 358
Study 25956286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 358
Study 23464664 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 10 mg
Number of subjects: 324
Study 23464664 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg
Number of subjects: 324
Study 23464664 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 40 mg
Number of subjects: 324
Study 23464664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 21318604 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 μg twice daily
Number of subjects: 60
Study 21318604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21318604 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 60
Study 18590587 — intervention group
Group type: EXPERIMENTAL
Intervention: NOPE-EGCG treatment (85 mg NOPE and 50 mg EGCG per capsule, two capsules per day)
Number of subjects: 138
Study 18590587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules per day)
Number of subjects: 138
Study 16466471 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet mode of health and health behavior questionnaires
Number of subjects: 270
Study 16466471 — intervention group
Group type: COMPARATOR
Intervention: Paper mode of health and health behavior questionnaires
Number of subjects: 270
Study 16466471 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet mode
Number of subjects: 270
Study 14764783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant human growth hormone (rhGH)
Number of subjects: 59
Study 14764783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 11579192 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 0
Study 11579192 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy
Number of subjects: 0
Study 11579192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both antipsychotic medication and behavioural therapy
Number of subjects: 0
Study 11579192 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trial of antipsychotic medication
Number of subjects: 0
Study 9137223 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial PTCA
Number of subjects: 900
Study 9137223 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbrachial PTCA
Number of subjects: 900
Study 9137223 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral PTCA
Number of subjects: 900
Study 7896367 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary calcium-creatinine ratio (Uca/Ucr)
Number of subjects: 352
Study 3450522 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (once daily)
Number of subjects: 22
Study 3450522 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (twice daily)
Number of subjects: 22
Study 29373235 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (1 mg/kg per day for 3 days)
Number of subjects: 605
Study 29373235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study 27825313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist medication therapy management (MTM)
Number of subjects: 47
Study 27825313 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 47
Study 25693889 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine at 120 ng/mL
Number of subjects: 36
Study 25693889 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine at 240 ng/mL
Number of subjects: 36
Study 25693889 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine at 180 ng/mL and 360 ng/mL
Number of subjects: 36
Study 25693889 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine at 120 ng/mL and 240 ng/mL
Number of subjects: 36
Study 25693889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23669628 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folic acid (4 mg/day)
Number of subjects: 268
Study 23669628 — intervention group
Group type: COMPARATOR
Intervention: Low-dose folic acid (0.4 mg/day)
Number of subjects: 268
Study 23669628 — intervention group
Group type: COMPARATOR
Intervention: Population rate (Brazilian population)
Number of subjects: 268
Study 21679353 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (Symbicort® SMART®) 160/4.5 µg twice daily plus 160/4.5 µg for symptom relief
Number of subjects: 1835
Study 21679353 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 1835
Study 21679353 — intervention group
Group type: COMPARATOR
Intervention: Conventional best standard treatment (CBST)
Number of subjects: 1835
Study 19354338 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-costing
Number of subjects: 0
Study 19354338 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross-costing
Number of subjects: 0
Study 19354338 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear model (GLM)
Number of subjects: 0
Study 19354338 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis of cost
Number of subjects: 0
Study 16713340 — intervention group
Group type: EXPERIMENTAL
Intervention: People with insomnia (PWI)
Number of subjects: 703
Study 16713340 — intervention group
Group type: COMPARATOR
Intervention: People not having insomnia (PNI)
Number of subjects: 703
Study 16713340 — intervention group
Group type: EXPERIMENTAL
Intervention: African-Americans
Number of subjects: 703
Study 16713340 — intervention group
Group type: COMPARATOR
Intervention: Caucasians
Number of subjects: 703
Study 16713340 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender, age group, and season
Number of subjects: 703
Study 16713340 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve analysis
Number of subjects: 703
Study 12890205 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% DFO in aqueous cream
Number of subjects: 18
Study 12890205 — intervention group
Group type: COMPARATOR
Intervention: Aqueous cream alone (Control)
Number of subjects: 18
Study 12890205 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% ALA with 20% DFO
Number of subjects: 18
Study 12890205 — intervention group
Group type: COMPARATOR
Intervention: 20% ALA (Control)
Number of subjects: 18
Study 10702175 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid supplement (25 mg total carotenoids/d)
Number of subjects: 0
Study 10702175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of carotenoids and vitamin E (335 mg RRR-alpha-tocopherol/d)
Number of subjects: 0
Study 10702175 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8836263 — intervention group
Group type: EXPERIMENTAL
Intervention: High spinal intraoperative block to T4 using 6mls of 0.5% bupivacaine plus continuous epidural 0.125% bupivacaine/0.0025% diamorphine
Number of subjects: 20
Study 8836263 — intervention group
Group type: COMPARATOR
Intervention: Epidural 0.5% bupivacaine block to T4 plus continuous epidural infusion of 0.125% bupivacaine/0.0025% diamorphine
Number of subjects: 20
Study 1290723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sizofiran and recombinant interferon-gamma before and after SLL, followed by human lymphoblastoid interferon-alpha
Number of subjects: 24
Study 1290723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug therapy)
Number of subjects: 24
Study 6367415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 150 mg/day
Number of subjects: 20
Study 6367415 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/day
Number of subjects: 20
Study 6367415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31005162 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram based on joint T2WI and DWI
Number of subjects: 96
Study 31005162 — intervention group
Group type: COMPARATOR
Intervention: Nomogram based only on clinicopathologic risk factors
Number of subjects: 96
Study 28341278 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic alignment TKA
Number of subjects: 877
Study 28341278 — intervention group
Group type: COMPARATOR
Intervention: Conventional alignment TKA
Number of subjects: 877
Study 27301469 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (pulmonary vasodilator)
Number of subjects: 151
Study 27301469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 27301469 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary arterial hypertension
Number of subjects: 151
Study 27301469 — intervention group
Group type: COMPARATOR
Intervention: HF with preserved ejection fraction
Number of subjects: 151
Study 27301469 — intervention group
Group type: COMPARATOR
Intervention: HF with reduced ejection fraction
Number of subjects: 151
Study 27301469 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study 27301469 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HF patients (n=103)
Number of subjects: 151
Study 25126027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive regimen (IAR) defined as ≥ 3 antihypertensives including a diuretic
Number of subjects: 284
Study 25126027 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 284
Study 22196033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5mg/kg
Number of subjects: 827
Study 22196033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15mg/kg
Number of subjects: 827
Study 22196033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 827
Study 22196033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 827
Study 19752011 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT RENEWAL
Number of subjects: 1274
Study 19752011 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk score from CRT RENEWAL
Number of subjects: 1274
Study 19752011 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression model and clinical risk score applied to HF-HRV study
Number of subjects: 1274
Study 17526166 — intervention group
Group type: EXPERIMENTAL
Intervention: Suanzaoren Decoction (SZRD)
Number of subjects: 60
Study 17526166 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive therapy (control group)
Number of subjects: 60
Study 15657021 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Monitoring of Blood Glucose (SMBG) + Hypoglycemia Anticipation, Awareness and Treatment Training (HAATT)
Number of subjects: 60
Study 15657021 — intervention group
Group type: COMPARATOR
Intervention: Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 60
Study 15657021 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Monitoring of Blood Glucose (SMBG) + HAATT
Number of subjects: 60
Study 11220796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet
Number of subjects: 63
Study 11220796 — intervention group
Group type: COMPARATOR
Intervention: Non-tourniquet
Number of subjects: 63
Study 9734351 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with asthma and wheezing (51 children)
Number of subjects: 1388
Study 9734351 — intervention group
Group type: COMPARATOR
Intervention: Children with wheezing alone (69 children)
Number of subjects: 1388
Study 8126510 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (deprenyl) with or without tocopherol
Number of subjects: 0
Study 8126510 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (deprenyl)
Number of subjects: 0
Study 3288845 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14 (2.5 mg)
Number of subjects: 20
Study 3288845 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (E2V) (2 mg)
Number of subjects: 20
Study 3288845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31770329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Number of subjects: 110
Study 31770329 — intervention group
Group type: COMPARATOR
Intervention: Orotracheal intubation
Number of subjects: 110
Study 31770329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intubation modes
Number of subjects: 110
Study 31288822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride
Number of subjects: 60
Study 31288822 — intervention group
Group type: COMPARATOR
Intervention: Propofol with placebo (0.9% sodium chloride solution)
Number of subjects: 60
Study 28492193 — intervention group
Group type: EXPERIMENTAL
Intervention: Live modeling intervention
Number of subjects: 98
Study 28492193 — intervention group
Group type: EXPERIMENTAL
Intervention: TPD technique with customized playing dental objects
Number of subjects: 98
Study 26457059 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1.5-2 mg/kg/day divided into three doses)
Number of subjects: 100
Study 26457059 — intervention group
Group type: COMPARATOR
Intervention: Silver nitrate cautery
Number of subjects: 100
Study 23591599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 2, 6, or 10 mg/kg on days 1, 15, and 43, followed by maintenance dosing every 8 weeks
Number of subjects: 72
Study 21479563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic lithotripter
Number of subjects: 80
Study 21479563 — intervention group
Group type: COMPARATOR
Intervention: Holmium: YAG laser
Number of subjects: 80
Study 18672764 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinkeshu Tablet (XKS)
Number of subjects: 60
Study 18672764 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 60
Study 16205924 — intervention group
Group type: EXPERIMENTAL
Intervention: 9NC administered with food (standard meal)
Number of subjects: 16
Study 16205924 — intervention group
Group type: COMPARATOR
Intervention: 9NC administered under fasting conditions
Number of subjects: 16
Study 16205924 — intervention group
Group type: EXPERIMENTAL
Intervention: 9AC administered with food (standard meal)
Number of subjects: 16